By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Retrophin, Inc. 

777 Third Avenue
22nd Floor
New York  New York  10017  U.S.A.
Phone: 646-564–3680 Fax:



Company News
Retrophin (RTRX) Receives European Orphan Drug Designation For Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis 11/16/2015 10:52:17 AM
Retrophin (RTRX) Announces Research Collaboration With The Grace Wilsey Foundation And The Warren Family Research Center For Drug Discovery And Development At University of Notre Dame 11/5/2015 11:57:57 AM
Retrophin (RTRX) To Present At The Leerink Partners 4th Annual Rare Disease Roundtable 9/17/2015 10:52:10 AM
Retrophin (RTRX) Sues Ousted CEO Martin Shkreli for $65 Million 8/17/2015 9:07:00 AM
Former Retrophin (RTRX) CEO Nabs $90 Million for Startup Turing Pharma 8/10/2015 6:08:07 AM
Retrophin (RTRX) Reports Second Quarter 2015 Financial Results 8/5/2015 11:26:44 AM
Retrophin (RTRX) To Report Second Quarter 2015 Financial Results 7/22/2015 10:53:17 AM
Retrophin (RTRX) Closes Sale Of Priority Review Voucher 7/7/2015 11:09:00 AM
Retrophin (RTRX) Receives Fast Track Designation For RE-024 For The Treatment Of Pantothenate Kinase-Associated Neurodegeneration 6/5/2015 9:34:06 AM
Retrophin (RTRX) Banks $245 Million From Sanofi (SAN.PA) for Priority Review Voucher 5/27/2015 8:07:50 AM